These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 11851731)

  • 41. Botulinum neurotoxin serotypes A and C do not affect motor units survival in humans: an electrophysiological study by motor units counting.
    Eleopra R; Tugnoli V; Quatrale R; Gastaldo E; Rossetto O; De Grandis D; Montecucco C
    Clin Neurophysiol; 2002 Aug; 113(8):1258-64. PubMed ID: 12140005
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The use of botulinum toxin type-B in the treatment of patients who have become unresponsive to botulinum toxin type-A -- initial experiences.
    Barnes MP; Best D; Kidd L; Roberts B; Stark S; Weeks P; Whitaker J
    Eur J Neurol; 2005 Dec; 12(12):947-55. PubMed ID: 16324088
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Recovery from botulinum neurotoxin poisoning in vivo.
    Keller JE
    Neuroscience; 2006 May; 139(2):629-37. PubMed ID: 16490322
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Binding and transcytosis of botulinum neurotoxin by polarized human colon carcinoma cells.
    Maksymowych AB; Simpson LL
    J Biol Chem; 1998 Aug; 273(34):21950-7. PubMed ID: 9705335
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The science and manufacturing behind botulinum neurotoxin type A-ABO in clinical use.
    Wortzman MS; Pickett A
    Aesthet Surg J; 2009 Nov; 29(6 Suppl):S34-42. PubMed ID: 19945003
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia.
    Chapman MA; Barron R; Tanis DC; Gill CE; Charles PD
    Clin Ther; 2007 Jul; 29(7):1325-37. PubMed ID: 17825685
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of botulinum toxins A and B in the aesthetic treatment of facial rhytides.
    Sadick NS; Herman AR
    Dermatol Surg; 2003 Apr; 29(4):340-7. PubMed ID: 12656810
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Are botulinum toxin type A preparations really the same medication? A comparison of three botulinum toxin A for variations in labelled neurological indications].
    Sławek J; Car H; Bonikowski M; Bogucki A; Koziorowski D; Potulska-Chromik A; Rudzińska M
    Neurol Neurochir Pol; 2010; 44(1):43-64. PubMed ID: 20358485
    [TBL] [Abstract][Full Text] [Related]  

  • 49. More than at the neuromuscular synapse: actions of botulinum neurotoxin A in the central nervous system.
    Mazzocchio R; Caleo M
    Neuroscientist; 2015 Feb; 21(1):44-61. PubMed ID: 24576870
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Protective potential of recombinant non-purified botulinum neurotoxin serotypes C and D.
    Moreira C; da Cunha CE; Moreira GM; Mendonça M; Salvarani FM; Moreira ÂN; Conceição FR
    Anaerobe; 2016 Aug; 40():58-62. PubMed ID: 27236078
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An assay for botulinum toxin types A, B and F that requires both functional binding and catalytic activities within the neurotoxin.
    Evans ER; Skipper PJ; Shone CC
    J Appl Microbiol; 2009 Oct; 107(4):1384-91. PubMed ID: 19426271
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Complete DNA sequences of the botulinum neurotoxin complex of Clostridium botulinum type A-Hall (Allergan) strain.
    Zhang L; Lin WJ; Li S; Aoki KR
    Gene; 2003 Oct; 315():21-32. PubMed ID: 14557061
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Botulinum toxin type B de novo therapy of cervical dystonia: frequency of antibody induced therapy failure.
    Dressler D; Bigalke H
    J Neurol; 2005 Aug; 252(8):904-7. PubMed ID: 15761672
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacology of therapeutic botulinum toxin preparations.
    Dressler D; Benecke R
    Disabil Rehabil; 2007 Dec; 29(23):1761-8. PubMed ID: 18033601
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The basic science of botulinum toxin.
    Lam SM
    Facial Plast Surg Clin North Am; 2003 Nov; 11(4):431-8. PubMed ID: 15062246
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical duration of action of different botulinum toxin types in humans.
    Eleopra R; Rinaldo S; Montecucco C; Rossetto O; Devigili G
    Toxicon; 2020 May; 179():84-91. PubMed ID: 32184153
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Chelation of zinc antagonizes the neuromuscular blocking properties of the seven serotypes of botulinum neurotoxin as well as tetanus toxin.
    Simpson LL; Coffield JA; Bakry N
    J Pharmacol Exp Ther; 1993 Nov; 267(2):720-7. PubMed ID: 8246147
    [TBL] [Abstract][Full Text] [Related]  

  • 58. DNA vaccines targeting heavy chain C-terminal fragments of Clostridium botulinum neurotoxin serotypes A, B, and E induce potent humoral and cellular immunity and provide protection from lethal toxin challenge.
    Scott VL; Villarreal DO; Hutnick NA; Walters JN; Ragwan E; Bdeir K; Yan J; Sardesai NY; Finnefrock AC; Casimiro DR; Weiner DB
    Hum Vaccin Immunother; 2015; 11(8):1961-71. PubMed ID: 26158319
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Botulinum neurotoxin: the neuromuscular junction revisited.
    Coffield JA
    Crit Rev Neurobiol; 2003; 15(3-4):175-96. PubMed ID: 15248810
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A natural human IgM antibody that neutralizes botulinum neurotoxin in vivo.
    Adekar SP; Al-Saleem FH; Elias MD; Rybinski KA; Simpson LL; Dessain SK
    Hybridoma (Larchmt); 2008 Apr; 27(2):65-9. PubMed ID: 18642670
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.